Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.80
FLML's Cash to Debt is ranked higher than
54% of the 1239 Companies
in the Global Biotechnology industry.

( Industry Median: 60.65 vs. FLML: 0.80 )
FLML' s 10-Year Cash to Debt Range
Min: 0.08   Max: No Debt
Current: 0.8

Equity to Asset 0.24
FLML's Equity to Asset is ranked higher than
53% of the 922 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. FLML: 0.24 )
FLML' s 10-Year Equity to Asset Range
Min: -0.32   Max: 0.8
Current: 0.24

-0.32
0.8
F-Score: 4
Z-Score: -0.37
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -196.84
FLML's Operating margin (%) is ranked higher than
66% of the 1013 Companies
in the Global Biotechnology industry.

( Industry Median: -78.59 vs. FLML: -196.84 )
FLML' s 10-Year Operating margin (%) Range
Min: -222.94   Max: 15.94
Current: -196.84

-222.94
15.94
Net-margin (%) -172.76
FLML's Net-margin (%) is ranked higher than
67% of the 1013 Companies
in the Global Biotechnology industry.

( Industry Median: -70.38 vs. FLML: -172.76 )
FLML' s 10-Year Net-margin (%) Range
Min: -191.26   Max: 22.56
Current: -172.76

-191.26
22.56
ROE (%) -174.13
FLML's ROE (%) is ranked higher than
54% of the 1134 Companies
in the Global Biotechnology industry.

( Industry Median: -34.93 vs. FLML: -174.13 )
FLML' s 10-Year ROE (%) Range
Min: -408.97   Max: 30.36
Current: -174.13

-408.97
30.36
ROA (%) -34.92
FLML's ROA (%) is ranked higher than
70% of the 1239 Companies
in the Global Biotechnology industry.

( Industry Median: -28.51 vs. FLML: -34.92 )
FLML' s 10-Year ROA (%) Range
Min: -53.63   Max: 14.58
Current: -34.92

-53.63
14.58
ROC (Joel Greenblatt) (%) -258.46
FLML's ROC (Joel Greenblatt) (%) is ranked higher than
75% of the 1212 Companies
in the Global Biotechnology industry.

( Industry Median: -442.83 vs. FLML: -258.46 )
FLML' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -501.46   Max: 76.01
Current: -258.46

-501.46
76.01
Revenue Growth (%) -16.70
FLML's Revenue Growth (%) is ranked higher than
68% of the 717 Companies
in the Global Biotechnology industry.

( Industry Median: -1.90 vs. FLML: -16.70 )
FLML' s 10-Year Revenue Growth (%) Range
Min: -16.7   Max: 42.6
Current: -16.7

-16.7
42.6
EBITDA Growth (%) 120.40
FLML's EBITDA Growth (%) is ranked higher than
99% of the 707 Companies
in the Global Biotechnology industry.

( Industry Median: -4.60 vs. FLML: 120.40 )
FLML' s 10-Year EBITDA Growth (%) Range
Min: -50.2   Max: 120.4
Current: 120.4

-50.2
120.4
EPS Growth (%) 65.90
FLML's EPS Growth (%) is ranked higher than
98% of the 723 Companies
in the Global Biotechnology industry.

( Industry Median: -7.40 vs. FLML: 65.90 )
FLML' s 10-Year EPS Growth (%) Range
Min: -38.2   Max: 88.8
Current: 65.9

-38.2
88.8
» FLML's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

FLML Guru Trades in

FLML Guru Trades in

Q2 2012

FLML Guru Trades in Q2 2012

Jim Simons 89,300 sh (+1.02%)
» More
Q3 2012

FLML Guru Trades in Q3 2012

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with FLML

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Jean-Marie Eveillard 2012-03-31 Sold Out 0.0048%$5.08 - $7.67 $ 14.33148%0
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 13.80
FLML's P/B is ranked higher than
62% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 5.76 vs. FLML: 13.80 )
FLML' s 10-Year P/B Range
Min: 1.83   Max: 14.22
Current: 13.8

1.83
14.22
P/S 15.10
FLML's P/S is ranked higher than
79% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 32.74 vs. FLML: 15.10 )
FLML' s 10-Year P/S Range
Min: 2.3   Max: 36.69
Current: 15.1

2.3
36.69
EV-to-EBIT -9.64
FLML's EV-to-EBIT is ranked lower than
54% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. FLML: -9.64 )
FLML' s 10-Year EV-to-EBIT Range
Min: -116.5   Max: 407.7
Current: -9.64

-116.5
407.7
Current Ratio 2.08
FLML's Current Ratio is ranked higher than
60% of the 1228 Companies
in the Global Biotechnology industry.

( Industry Median: 4.73 vs. FLML: 2.08 )
FLML' s 10-Year Current Ratio Range
Min: 0.57   Max: 6.76
Current: 2.08

0.57
6.76
Quick Ratio 1.94
FLML's Quick Ratio is ranked higher than
62% of the 1228 Companies
in the Global Biotechnology industry.

( Industry Median: 4.53 vs. FLML: 1.94 )
FLML' s 10-Year Quick Ratio Range
Min: 0.52   Max: 6.7
Current: 1.94

0.52
6.7

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 2.50
FLML's Price/Median PS Value is ranked higher than
75% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 2.90 vs. FLML: 2.50 )
FLML' s 10-Year Price/Median PS Value Range
Min: 0.24   Max: 5.55
Current: 2.5

0.24
5.55
Earnings Yield (Greenblatt) -10.40
FLML's Earnings Yield (Greenblatt) is ranked higher than
67% of the 1174 Companies
in the Global Biotechnology industry.

( Industry Median: -6.40 vs. FLML: -10.40 )
FLML' s 10-Year Earnings Yield (Greenblatt) Range
Min: -10.4   Max: 2.8
Current: -10.4

-10.4
2.8
Forward Rate of Return (Yacktman) 71.06
FLML's Forward Rate of Return (Yacktman) is ranked higher than
99% of the 832 Companies
in the Global Biotechnology industry.

( Industry Median: -6.41 vs. FLML: 71.06 )
FLML' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -62   Max: 68.8
Current: 71.06

-62
68.8

Business Description

Industry: Biotechnology » Biotechnology
Compare:LH, ALR, DGX, LIFE, ENZ » details
Traded in other countries:FL3.Germany
Flamel Technologies was incorporated as a Societe Anonyme or SA, a form of corporation under the laws of the Republic of France in August 1990 as Flamel Technologies S.A. The Company is a specialty pharmaceutical company with a history in drug delivery, working on the development of safer and more efficacious formulations. The acquisition of Éclat on March 13, 2012 has created a more vertically integrated company, benefiting from greater development and commercial expertise and more near-term and mid-term potential value creating catalysts. Since its acquisition of Eclat, Flamel is now engaged in not only on the development and licensing of versatile, proprietary drug delivery platforms but also on the development of novel, high-value products based on those delivery platforms. Bloxiverz, the Company first NDA approval from the portfolio of Eclat products acquired in March 2012. Bloxiverz's NDA was filed in August 2012 and approved by the FDA on May 2013. The launch of Bloxiverz commenced in July 2013. Bloxiverz is a drug used intravenously in the operating room for the reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery. Bloxiverz is the first and only FDA-approved version of neostigmine methylsulfate, even though other versions of neostigmine have been on the market as unapproved, grandfathered products under the Food, Drug and Cosmetic Act of 1938. Coreg CR, the lead product using its Micropump drug delivery platform. Coreg CR is an extended-release formulation once-a-day of Coreg a non-selective antagonist of Beta 1, Beta 2 adrenergic receptors and a selective antagonist of Alpha 1 adrenergic receptors. The Company faces competition from Actavis, Alkermes, BioAlliance Pharma, Depomed, Ethypharm, Octoplus, Veloxis Pharmaceuticals, Nektar Therapeutics. The Company owns and develops drug delivery platforms that are able to tackle key challenges in the formulation, in various dosage forms of a broad range of drugs novel, already-marketed, or off-patent that includes Micropump. During the 2013 the Company has 395 patents in total. The design, testing, manufacturing and marketing of certain new or substantially modified drugs, biological products or medical devices must be approved, cleared or certified by regulatory agencies, regulatory authorities and Notified Bodies under applicable laws and regulations, the requirements of which may vary from country to country.
» More Articles for FLML

Headlines

Articles On GuruFocus.com
Flamel Technologies to Report Third Quarter of Fiscal Year 2014 Results Oct 21 2014 
Flamel Technologies Announces Positive Results of First-in-Man Clinical Trial With LiquiTime(R) Ibup Oct 15 2014 
Flamel Technologies Announces Second Quarter 2009 Results; Multiple New Projects; Cash Increases fro Aug 05 2009 
Flamel Technologies Announces Projected Release Date of Second Quarter Results; Conference Call Jul 28 2009 

More From Other Websites
Nasdaq stocks posting largest percentage increases Nov 26 2014
Flamel Technologies (FLML) in Focus: Stock Rises 11% Nov 14 2014
Flamel Technologies (FLML) Crumbles: Stock Falls by 7.1% Nov 03 2014
Flamel Technologies Announces Third Quarter Results of Fiscal Year 2014 Oct 31 2014
Flamel Technologies Announces Third Quarter Results of Fiscal Year 2014 Oct 31 2014
Q3 2014 Flamel Technologies SA Earnings Release - Before Market Open Oct 31 2014
Flamel Technologies to Report Third Quarter of Fiscal Year 2014 Results Oct 21 2014
Flamel Technologies to Report Third Quarter of Fiscal Year 2014 Results Oct 21 2014
Flamel Technologies Announces Positive Results of First-in-Man Clinical Trial With LiquiTime(R)... Sep 29 2014
Can Stratasys and Flamel Make You Money? Sep 11 2014
Flamel Technologies Announces Plan to Appoint New VP of R&D Sep 11 2014
Flamel Technologies SA (FLML) in Focus: Stock Rises 8% Aug 22 2014
Flamel Technologies SA (FLML) Soars: Stock Rises 10.9% Aug 05 2014
Flamel Notified of FDA Communication to Unapproved Manufacturers of Neostigmine Methylsulfate Aug 04 2014
Flamel Technologies Announces Second Quarter of Fiscal Year 2014 Results Jul 29 2014
Flamel Technologies to Report Second Quarter of Fiscal Year 2014 Results Jul 22 2014
Weakness Seen in Lannett Company (LCI): Stock Tumbles 17.1% Jul 17 2014
Flamel Technologies has multiple catalysts in second half, says Summer Street Jul 16 2014
Flamel Technologies: Bloxiverz Competition To Cease Marketing Jul 09 2014
Flamel Technologies Announces Results of 2014 Annual Meeting Jul 02 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK